Regulatory FDA clears first genetic hearing loss gene therapy PharmaphorumRegeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.RegulatoryGene TherapyRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaphorum Regeneron’s Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US. RegulatoryGene TherapyRead full story Post navigation Previous: Cumberland to sell drug portfolio to Apotex for $100mNext: Cumberland to sell drug portfolio to Apotex for $100m Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026